{"id":895509,"date":"2025-10-14T09:26:13","date_gmt":"2025-10-14T13:26:13","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/armata-pharmaceuticals-to-present-late-breaking-clinical-data-highlighting-its-staphylococcus-aureus-bacteriophage-cocktail-ap-sa02-at-idweek-2025\/"},"modified":"2025-10-14T09:26:13","modified_gmt":"2025-10-14T13:26:13","slug":"armata-pharmaceuticals-to-present-late-breaking-clinical-data-highlighting-its-staphylococcus-aureus-bacteriophage-cocktail-ap-sa02-at-idweek-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/armata-pharmaceuticals-to-present-late-breaking-clinical-data-highlighting-its-staphylococcus-aureus-bacteriophage-cocktail-ap-sa02-at-idweek-2025\/","title":{"rendered":"Armata Pharmaceuticals to Present Late-Breaking Clinical Data highlighting its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, at IDWeek 2025\u2122"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n
\n LOS ANGELES<\/span>
\n <\/span>, Oct. 14, 2025<\/span><\/span> \/PRNewswire\/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced it will be presenting late-breaking Phase 2a clinical data on its Staphylococcus aureus<\/i> bacteriophage cocktail, AP-SA02, at IDWeek 2025\u2122<\/b><\/sup>, which is being held October 19-22, 2025<\/span>, in Atlanta, GA.<\/span><\/p>\n

\n

\n
\n \"Armata
\n <\/a>\n <\/p>\n<\/p><\/div>\n

\n Details of the oral presentation are as follows:<\/b>\n <\/p>\n

\n\n\n\n\n\n\n\n
\n

\n
\n Presentation Title:\u00a0 \u00a0 \u00a0 \u00a0 \u00a0<\/b>
\n <\/span>\n <\/p>\n<\/td>\n

\n

\n A Phase 2a Randomized, Double-Blind, Controlled Trial of the Efficacy and Safety of an Intravenous (IV) Bacteriophage Cocktail (AP-SA02) vs. Placebo in Combination with Best Available Antibiotic Therapy (BAT) in Patients with Complicated Staphylococcus aureus<\/i> Bacteremia<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n
\n Presenter:<\/b>
\n <\/span>\n <\/p>\n<\/td>\n

\n

\n Dr. Loren G. Miller, M.D., M.P.H., Professor of Medicine, David Geffen School of Medicine at UCLA, Chief, Division of Infectious Diseases at Harbor-UCLA Medical Center and the Lundquist Institute<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n
\n Session:<\/b>\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0<\/span>\n <\/p>\n<\/td>\n

\n

\n Late Breaking Info That May Change Your Approach To Bacterial and Fungal Infections<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n
\n Location:\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0<\/b>
\n <\/span>\n <\/p>\n<\/td>\n

\n

\n B401-B402<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n
\n Date:\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\u00a0<\/b>
\n <\/span>\n <\/p>\n<\/td>\n

\n

\n Wednesday, October 22, 2025<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n
\n Time:<\/b> \u00a0<\/span>\n <\/p>\n<\/td>\n

\n

\n 10:30 AM – 11:45 AM ET<\/span>\n <\/p>\n<\/td>\n<\/tr>\n<\/table><\/div>\n

\n About IDWeek 2025\u2122
<\/sup><\/b>IDWeek 2025\u2122<\/b><\/sup>\u00a0is a joint annual meeting of the Infectious Diseases Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA), the Pediatric Infectious Diseases Society (PIDS) and the Society of Infectious Diseases Pharmacists (SIDP). With the theme “Advancing Science, Improving Care,” IDWeek features the latest science and bench-to-bedside approaches in prevention, diagnosis, treatment and epidemiology of infectious diseases, including HIV, across the lifespan. IDWeek 2025\u2122<\/b><\/sup>\u00a0takes place October 19-22<\/span> in Atlanta, GA.<\/span> For more information, visit www.idweek.org<\/a>.<\/p>\n

\n About AP-SA02 and\u00a0diSArm Study
<\/b>Armata is developing AP-SA02, a fixed multi-phage phage cocktail, for the treatment of complicated bacteremia caused by Staphylococcus aureus <\/i>(S. aureus<\/i>), including methicillin-sensitive S. aureus<\/i> (MSSA) and methicillin-resistant S. aureus<\/i> (MRSA) strains.<\/p>\n

The diSArm study (NCT05184764<\/a>) is a Phase 1b<\/span>\/2a, multicenter, randomized, double-blind, placebo-controlled, multiple ascending dose escalation study of the safety, tolerability, and efficacy of intravenous AP-SA02 in addition to best available antibiotic therapy (BAT) compared to BAT alone (placebo) for the treatment of adults with complicated S. aureus<\/i> bacteremia. The results from the diSArm study are an important step forward in Armata’s effort to confirm the potent antimicrobial activity of phage therapy and the completion of the study represents a significant milestone in the development of AP-SA02, moving Armata one step closer to introducing an effective new treatment option to patients suffering from complicated S. aureus<\/i> bacteremia. diSArm represents the first clear evidence in a randomized controlled trial of the efficacy of phage against a serious systemic pathogen that is responsible for significant morbidity and mortality in the United States<\/span>.<\/p>\n

The Phase 1b<\/span>\/2a clinical development of AP-SA02 was partially supported by a $26.2 million<\/span> Department of Defense (DoD) award, received through the Medical Technology Enterprise Consortium (MTEC) and managed by the Naval Medical Research Command (NMRC) \u2013 Naval Advanced Medical Development (NAMD) with funding from the Defense Health Agency and Joint Warfighter Medical Research Program.<\/p>\n

\n About\u00a0Armata Pharmaceuticals, Inc.
<\/b>Armata is a clinical-stage biotechnology company focused on the development of high-purity pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus<\/i>, and other important pathogens. Armata is committed to advancing phage therapy with drug development expertise that spans bench to clinic including in-house phage-specific current Good Manufacturing Practices (“cGMP”) manufacturing to support full commercialization.<\/p>\n

\n Forward Looking Statements
<\/b>This communication contains “forward-looking” statements as defined by the Private Securities Litigation Reform Act of 1995. These statements relate to future events, results or to Armata’s future financial performance and involve known and unknown risks, uncertainties and other factors which may cause Armata’s actual results, performance or events to be materially different from any future results, performance or events expressed or implied by the forward-looking statements. In some cases, you can identify these statements by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” or the negative of those terms, and similar expressions. These forward-looking statements reflect management’s beliefs and views with respect to future events and are based on estimates and assumptions as of the date of this communication and are subject to risks and uncertainties including risks related to Armata’s development of bacteriophage-based therapies; ability to staff and maintain its production facilities under fully compliant cGMP; ability to meet anticipated milestones in the development and testing of the relevant product; ability to be a leader in the development of phage-based therapeutics; ability to achieve its vision, including improvements through engineering and success of clinical trials; ability to successfully complete preclinical and clinical development of, and obtain regulatory approval of its product candidates and commercialize any approved products on its expected timeframes or at all; and Armata’s estimates regarding anticipated operating losses, capital requirements and needs for additional funds. Additional risks and uncertainties relating to Armata and its business can be found under the caption “Risk Factors” and elsewhere in Armata’s filings and reports with the U.S. Securities and Exchange Commission (the “SEC”), including in Armata’s Annual Report on Form 10-K, filed with the SEC on March 21, 2025<\/span>, and in its subsequent filings with the SEC.<\/p>\n

Armata expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Armata’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.\u00a0<\/p>\n

\n Media Contacts:<\/b>\n <\/p>\n

\n At\u00a0Armata:<\/b>\n <\/p>\n

Pierre\u00a0Kyme
ir@armatapharma.com<\/a>
310-665-2928<\/p>\n

\n Investor Relations:<\/b>\n <\/p>\n

\n Joyce Allaire<\/span>
\n
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com<\/a>
212-915-2569<\/p>\n

\n \"Cision\" View original content to download multimedia:https:\/\/www.prnewswire.com\/news-releases\/armata-pharmaceuticals-to-present-late-breaking-clinical-data-highlighting-its-staphylococcus-aureus-bacteriophage-cocktail-ap-sa02-at-idweek-2025-302582563.html<\/a><\/p>\n

SOURCE Armata Pharmaceuticals, Inc.<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire LOS ANGELES , Oct. 14, 2025 \/PRNewswire\/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced it will be presenting late-breaking Phase 2a clinical data on its Staphylococcus aureus bacteriophage cocktail, AP-SA02, at IDWeek 2025\u2122, which is being held October 19-22, 2025, in Atlanta, GA. Details of the oral presentation are as follows: Presentation Title:\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 A Phase 2a Randomized, Double-Blind, Controlled Trial of the Efficacy and Safety of an Intravenous (IV) Bacteriophage Cocktail (AP-SA02) vs. Placebo in Combination with Best Available Antibiotic Therapy (BAT) in Patients with Complicated … <\/p>\n

Continue reading “Armata Pharmaceuticals to Present Late-Breaking Clinical Data highlighting its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, at IDWeek 2025\u2122”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-895509","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nArmata Pharmaceuticals to Present Late-Breaking Clinical Data highlighting its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, at IDWeek 2025\u2122 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/armata-pharmaceuticals-to-present-late-breaking-clinical-data-highlighting-its-staphylococcus-aureus-bacteriophage-cocktail-ap-sa02-at-idweek-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Armata Pharmaceuticals to Present Late-Breaking Clinical Data highlighting its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, at IDWeek 2025\u2122 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire LOS ANGELES , Oct. 14, 2025 \/PRNewswire\/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced it will be presenting late-breaking Phase 2a clinical data on its Staphylococcus aureus bacteriophage cocktail, AP-SA02, at IDWeek 2025\u2122, which is being held October 19-22, 2025, in Atlanta, GA. Details of the oral presentation are as follows: Presentation Title:\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 A Phase 2a Randomized, Double-Blind, Controlled Trial of the Efficacy and Safety of an Intravenous (IV) Bacteriophage Cocktail (AP-SA02) vs. Placebo in Combination with Best Available Antibiotic Therapy (BAT) in Patients with Complicated … Continue reading "Armata Pharmaceuticals to Present Late-Breaking Clinical Data highlighting its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, at IDWeek 2025\u2122"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/armata-pharmaceuticals-to-present-late-breaking-clinical-data-highlighting-its-staphylococcus-aureus-bacteriophage-cocktail-ap-sa02-at-idweek-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-14T13:26:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/884786\/Armata_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/armata-pharmaceuticals-to-present-late-breaking-clinical-data-highlighting-its-staphylococcus-aureus-bacteriophage-cocktail-ap-sa02-at-idweek-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/armata-pharmaceuticals-to-present-late-breaking-clinical-data-highlighting-its-staphylococcus-aureus-bacteriophage-cocktail-ap-sa02-at-idweek-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Armata Pharmaceuticals to Present Late-Breaking Clinical Data highlighting its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, at IDWeek 2025\u2122\",\"datePublished\":\"2025-10-14T13:26:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/armata-pharmaceuticals-to-present-late-breaking-clinical-data-highlighting-its-staphylococcus-aureus-bacteriophage-cocktail-ap-sa02-at-idweek-2025\\\/\"},\"wordCount\":988,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/armata-pharmaceuticals-to-present-late-breaking-clinical-data-highlighting-its-staphylococcus-aureus-bacteriophage-cocktail-ap-sa02-at-idweek-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/884786\\\/Armata_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/armata-pharmaceuticals-to-present-late-breaking-clinical-data-highlighting-its-staphylococcus-aureus-bacteriophage-cocktail-ap-sa02-at-idweek-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/armata-pharmaceuticals-to-present-late-breaking-clinical-data-highlighting-its-staphylococcus-aureus-bacteriophage-cocktail-ap-sa02-at-idweek-2025\\\/\",\"name\":\"Armata Pharmaceuticals to Present Late-Breaking Clinical Data highlighting its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, at IDWeek 2025\u2122 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/armata-pharmaceuticals-to-present-late-breaking-clinical-data-highlighting-its-staphylococcus-aureus-bacteriophage-cocktail-ap-sa02-at-idweek-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/armata-pharmaceuticals-to-present-late-breaking-clinical-data-highlighting-its-staphylococcus-aureus-bacteriophage-cocktail-ap-sa02-at-idweek-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/884786\\\/Armata_Logo.jpg\",\"datePublished\":\"2025-10-14T13:26:13+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/armata-pharmaceuticals-to-present-late-breaking-clinical-data-highlighting-its-staphylococcus-aureus-bacteriophage-cocktail-ap-sa02-at-idweek-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/armata-pharmaceuticals-to-present-late-breaking-clinical-data-highlighting-its-staphylococcus-aureus-bacteriophage-cocktail-ap-sa02-at-idweek-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/armata-pharmaceuticals-to-present-late-breaking-clinical-data-highlighting-its-staphylococcus-aureus-bacteriophage-cocktail-ap-sa02-at-idweek-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/884786\\\/Armata_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/884786\\\/Armata_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/armata-pharmaceuticals-to-present-late-breaking-clinical-data-highlighting-its-staphylococcus-aureus-bacteriophage-cocktail-ap-sa02-at-idweek-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Armata Pharmaceuticals to Present Late-Breaking Clinical Data highlighting its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, at IDWeek 2025\u2122\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Armata Pharmaceuticals to Present Late-Breaking Clinical Data highlighting its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, at IDWeek 2025\u2122 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/armata-pharmaceuticals-to-present-late-breaking-clinical-data-highlighting-its-staphylococcus-aureus-bacteriophage-cocktail-ap-sa02-at-idweek-2025\/","og_locale":"en_US","og_type":"article","og_title":"Armata Pharmaceuticals to Present Late-Breaking Clinical Data highlighting its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, at IDWeek 2025\u2122 - Market Newsdesk","og_description":"PR Newswire LOS ANGELES , Oct. 14, 2025 \/PRNewswire\/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced it will be presenting late-breaking Phase 2a clinical data on its Staphylococcus aureus bacteriophage cocktail, AP-SA02, at IDWeek 2025\u2122, which is being held October 19-22, 2025, in Atlanta, GA. Details of the oral presentation are as follows: Presentation Title:\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 A Phase 2a Randomized, Double-Blind, Controlled Trial of the Efficacy and Safety of an Intravenous (IV) Bacteriophage Cocktail (AP-SA02) vs. Placebo in Combination with Best Available Antibiotic Therapy (BAT) in Patients with Complicated … Continue reading \"Armata Pharmaceuticals to Present Late-Breaking Clinical Data highlighting its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, at IDWeek 2025\u2122\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/armata-pharmaceuticals-to-present-late-breaking-clinical-data-highlighting-its-staphylococcus-aureus-bacteriophage-cocktail-ap-sa02-at-idweek-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-10-14T13:26:13+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/884786\/Armata_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/armata-pharmaceuticals-to-present-late-breaking-clinical-data-highlighting-its-staphylococcus-aureus-bacteriophage-cocktail-ap-sa02-at-idweek-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/armata-pharmaceuticals-to-present-late-breaking-clinical-data-highlighting-its-staphylococcus-aureus-bacteriophage-cocktail-ap-sa02-at-idweek-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Armata Pharmaceuticals to Present Late-Breaking Clinical Data highlighting its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, at IDWeek 2025\u2122","datePublished":"2025-10-14T13:26:13+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/armata-pharmaceuticals-to-present-late-breaking-clinical-data-highlighting-its-staphylococcus-aureus-bacteriophage-cocktail-ap-sa02-at-idweek-2025\/"},"wordCount":988,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/armata-pharmaceuticals-to-present-late-breaking-clinical-data-highlighting-its-staphylococcus-aureus-bacteriophage-cocktail-ap-sa02-at-idweek-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/884786\/Armata_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/armata-pharmaceuticals-to-present-late-breaking-clinical-data-highlighting-its-staphylococcus-aureus-bacteriophage-cocktail-ap-sa02-at-idweek-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/armata-pharmaceuticals-to-present-late-breaking-clinical-data-highlighting-its-staphylococcus-aureus-bacteriophage-cocktail-ap-sa02-at-idweek-2025\/","name":"Armata Pharmaceuticals to Present Late-Breaking Clinical Data highlighting its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, at IDWeek 2025\u2122 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/armata-pharmaceuticals-to-present-late-breaking-clinical-data-highlighting-its-staphylococcus-aureus-bacteriophage-cocktail-ap-sa02-at-idweek-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/armata-pharmaceuticals-to-present-late-breaking-clinical-data-highlighting-its-staphylococcus-aureus-bacteriophage-cocktail-ap-sa02-at-idweek-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/884786\/Armata_Logo.jpg","datePublished":"2025-10-14T13:26:13+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/armata-pharmaceuticals-to-present-late-breaking-clinical-data-highlighting-its-staphylococcus-aureus-bacteriophage-cocktail-ap-sa02-at-idweek-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/armata-pharmaceuticals-to-present-late-breaking-clinical-data-highlighting-its-staphylococcus-aureus-bacteriophage-cocktail-ap-sa02-at-idweek-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/armata-pharmaceuticals-to-present-late-breaking-clinical-data-highlighting-its-staphylococcus-aureus-bacteriophage-cocktail-ap-sa02-at-idweek-2025\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/884786\/Armata_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/884786\/Armata_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/armata-pharmaceuticals-to-present-late-breaking-clinical-data-highlighting-its-staphylococcus-aureus-bacteriophage-cocktail-ap-sa02-at-idweek-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Armata Pharmaceuticals to Present Late-Breaking Clinical Data highlighting its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, at IDWeek 2025\u2122"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/895509","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=895509"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/895509\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=895509"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=895509"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=895509"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}